03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication. Sarcopenia...
17:44 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

FDA approves Xtandi for non-metastatic CRPC

FDA approved an sNDA for Xtandi enzalutamide from Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (Tokyo:4503) to treat non-metastatic castration-resistant prostate cancer (CRPC). The oral androgen receptor antagonist is already approved to treat metastatic CRPC. Pfizer...
18:57 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro, cell culture and mouse studies suggest inhibiting the DNAJ/Hsp70 chaperone axis could help treat castration-resistant prostate cancer (CRPC). Screening of a library of chalcone analogs and testing in cell-based signaling assays...
18:58 , May 25, 2018 |  BC Week In Review  |  Financial News

Kronos raises $18M seed round, names Bischofberger CEO

Cancer company Kronos Bio Inc. (New York, N.Y.) raised $18 million in seed financing May 23 and hired Norbert Bischofberger as president and CEO. Bischofberger was EVP of R&D and CSO of Gilead Sciences Inc....
18:23 , May 25, 2018 |  BC Week In Review  |  Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an...
21:16 , May 23, 2018 |  BC Extra  |  Financial News

Kronos raises seed round, names Bischofberger CEO

Cancer company Kronos Bio Inc. (Cambridge, Mass.) raised $18 million in seed financing Wednesday and hired Norbert Bischofberger as president and CEO. Bischofberger was EVP of R&D and CSO of Gilead Sciences Inc. (NASDAQ:GILD) until...
18:22 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting β-catenin in combination with Xtandi enzalutamide could help treat prostate cancer. In tumor samples from prostate cancer patients, levels of β-catenin were higher in...
20:40 , May 18, 2018 |  BioCentury  |  Finance

CellCentric’s magic trio

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes...
15:04 , May 18, 2018 |  BC Extra  |  Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an...
17:07 , Apr 6, 2018 |  BC Week In Review  |  Financial News

Arvinas raises $55M series C

Protein degradation company Arvinas LLC (New Haven, Conn.) raised $55 million in a series C round on April 4 led by new investor Nextech Invest. New investors Deerfield Management, Hillhouse Capital and Sirona Capital also...